Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAT | P04040 | 1/20 | 0.56 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23654599 | 1.00 | CAT (0.56) | CATNLRP3 | |
| SCHEMBL23654578 | 1.00 | CAT (0.56) | CATNLRP3 | |
| SCHEMBL21012423 | 0.93 | CAT (0.61) | CAT | |
| SCHEMBL23655053 | 0.93 | CAT (0.61) | CAT | |
| SCHEMBL21012459 | 0.89 | CAT (0.56) | CAT | |
| SCHEMBL23654597 | 0.89 | CAT (0.56) | CAT | |
| SCHEMBL21012461 | 0.88 | CAT (0.60) | CAT | |
| SCHEMBL23655280 | 0.88 | CAT (0.60) | CAT | |
| SCHEMBL23655316 | 0.87 | CAT (0.61) | CAT | |
| SCHEMBL21012442 | 0.87 | CAT (0.61) | CAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999759-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20220056055-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11180512-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3478693-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20200181177-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | THE MEDICINES COMPANY (SAN DIEGO), LLC | 2020-06-11 | — | — | US | disclosed |
| US-10570159-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190233443-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | disclosed |
| US-10294249-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2019-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056055-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BTD, BLK, BCL6B | CAT 106/4885NLRP3 384/4885 |
| US-10294249-B2 | Boronic acid derivatives and therapeutic uses thereof | BTD, BLK, BCL6B | CAT 106/4885NLRP3 384/4885 |
| US-20200181177-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BTD, BLK, BCL6B | CAT 106/4885NLRP3 384/4885 |
| US-10570159-B2 | Boronic acid derivatives and therapeutic uses thereof | BTD, BLK, BCL6B | CAT 106/4885NLRP3 384/4885 |
| US-11180512-B2 | Boronic acid derivatives and therapeutic uses thereof | BTD, BLK, BCL6B | CAT 106/4885NLRP3 384/4885 |
| US-11999759-B2 | Boronic acid derivatives and therapeutic uses thereof | BTD, BLK, BCL6B | CAT 106/4885NLRP3 384/4885 |
| US-20190233443-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BTD, BLK, BCL6B | CAT 106/4885NLRP3 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.